CYNA: Cynapsus Therapeutics Inc. - Summary | Jitta

Cynapsus Therapeutics Inc.

NASDAQ:CYNA

Notice
Stock data is unavailable or the company’s delisted.
Price
$40.48
Loss Chance
58.7%
1.35JITTA SCORE
n/a
Jitta Ranking
Sorry, the data is not yet available for this stock.
HISTORICAL JITTA SCORE
Related
Sorry, the data is not yet available for this stock.
Jitta Factors
Sorry, the data is not yet available for this stock.
Jitta Signs
Debt LevelNo Long Term Debt
New Share IssuedMore than 50% in 5 years
CapExVery High
Key Stats
Jitta Score
Jitta Line
1.35
n/a
COMPANY DESCRIPTION
Cynapsus Therapeutics Inc., a specialty central nervous system pharmaceutical company, engages in developing and preparing to commercialize a fast-acting sublingual thin film for debilitating OFF episodes associated with Parkinson’s disease (PD). The company’s drug candidate includes APL-130277, an easy-to-administer, sublingual thin film formulation of apomorphine that has completed a Phase II clinical trial for the treatment of OFF episodes for advanced PD patients. It has collaboration with The Michael J. Fox Foundation for Parkinson's research. The company was formerly known as Cannasat Therapeutics Inc. and changed its name to Cynapsus Therapeutics Inc. in April 2010. Cynapsus Therapeutics Inc. is headquartered in Toronto, Canada. As of October 21, 2016, Cynapsus Therapeutics Inc. operates as a subsidiary of Sunovion CNS Development Canada ULC.